Biological Markers Predicting Exercise Capacity in CF-LVAD Patients.

Biological Markers Predicting Exercise Capacity in Heart Failure Patients Supported With a Continuous-flow Left Ventricular Assist Device.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02303236

Enrollment

Registered

2014-11-27

Start date

2014-11-30

Completion date

2016-12-24

Last updated

2017-10-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Keywords

Exercise

Brief summary

Establishing the association between biological markers and exercise capacity in continuous-flow left ventricular assist device patients.

Detailed description

The aim of this study is to investigate if specific biological markers can predict exercise capacity in advanced heart failure patients supported with continuous-flow left ventricular assist device patients.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 90 Years

Healthy volunteers

Inclusion criteria

* Stable CF-LVAD patients.

Exclusion criteria

* Unstable CF-LVAD patients.

Design outcomes

Primary

Measure	Time frame	Description
Biological markers	Blood sampling on study day and samples are subsequently stored frozen.	Analysis of blood will be carried out on all samples simultaneously, expected markers are pro-BNP, MRproANP, copeptin, Gal-3 and proADM.

Secondary

Measure	Time frame	Description
Exercise capacity	Examination on study day. Patients will only be followed on the day of the study. Exercise testing is performed as the last intervention on the study day.	Exercise capacity will be estimated by peak VO2 measurements on a upright ergometer bike with breath-by-breath gas analysis.

Countries

Denmark

Outcome results